Oral Etoposide Dosing for Ovarian Cancer
For recurrent, platinum-resistant epithelial ovarian cancer, oral etoposide should be dosed at 50 mg daily for 14 days, repeated every 21 days (3-week cycles). This fixed-dose regimen provides the optimal balance of efficacy and tolerability in this heavily pretreated patient population.
Recommended Dosing Regimen
The standard approach is:
- 50 mg orally once daily for 14 consecutive days
- 7-day treatment-free interval
- Repeat cycle every 21 days
This fixed-dose schedule (50 mg/day × 14 days) is preferred over body surface area-based dosing (50-100 mg/m²/day) because it:
- Minimizes severe hematologic toxicity 1, 2
- Maintains manageable adverse effects in elderly and heavily pretreated patients 2
- Achieves clinical benefit rates of 40% with overall response rates of 19-26% 1, 3
Alternative regimens that have been studied include:
- 100 mg daily for 14 days every 3 weeks (higher toxicity, similar efficacy) 3
- 50 mg/m² daily for 21 days every 4 weeks (slightly longer exposure) 2, 4
The 50 mg fixed-dose, 14-day regimen is recommended as first choice due to superior tolerability 1.
Clinical Context and Efficacy
Oral etoposide is indicated for recurrent, platinum-resistant ovarian cancer (progression within 6 months of platinum therapy or platinum-refractory disease). The evidence shows:
- Response rates: 16-26% in platinum-resistant disease 2, 3
- Clinical benefit rate: 40% (partial response + stable disease) 1
- Median progression-free survival: 3.2 months 1
- Median overall survival: 6-10 months 1, 5
Patients with platinum-free intervals >6 months before etoposide initiation show significantly better outcomes (response rate 34.5% vs 5.4%, P<0.010) 6.
Dose Adjustments for Hepatic Impairment
Hepatic dysfunction requires caution but specific dose reductions are not well-defined 7. Based on FDA labeling:
- Mild hepatic impairment: No specific adjustment required, but monitor closely
- Moderate hepatic impairment: Consider empiric dose reduction (insufficient data for specific recommendations)
- Severe hepatic impairment: Avoid etoposide or use with extreme caution at reduced doses
The lack of precise hepatic dosing guidelines reflects limited pharmacokinetic data in this population 8. Monitor liver function tests at baseline and with each cycle 7.
Dose Adjustments for Renal Impairment
Renal function significantly impacts etoposide clearance. Dose reduction is mandatory for creatinine clearance <50 mL/min 7:
| Creatinine Clearance | Dose Adjustment |
|---|---|
| >50 mL/min | 100% of dose (50 mg daily) |
| 15-50 mL/min | 75% of dose (approximately 35-40 mg daily) |
| <15 mL/min | Further reduction required; insufficient data |
For the 50 mg daily regimen, patients with CrCl 15-50 mL/min should receive approximately 35-40 mg daily 7. Subsequent doses should be adjusted based on tolerance and hematologic toxicity.
Toxicity Monitoring and Management
Primary toxicity is myelosuppression, particularly neutropenia and thrombocytopenia 1, 2:
- Grade 3-4 hematologic toxicity: Occurs in 13-30% of patients
- Most common: Neutropenia (71-76%), anemia (90-96%), thrombocytopenia (49-57%) 5
- Non-hematologic: Generally mild; nausea, fatigue, alopecia less severe than with IV regimens 2
Monitoring requirements:
- Complete blood count before each cycle and weekly during treatment 7
- Hold treatment for ANC <1000/mm³ or platelets <50,000/mm³
- Resume at reduced dose if recovery takes >2 weeks 7
Key advantage: The 50 mg × 14-day schedule achieves median dose intensity of 83% (range 47-100%) with acceptable toxicity in elderly, heavily pretreated patients 2.
Pharmacokinetic Considerations
Low doses (50 mg/day) optimize bioavailability while avoiding saturable absorption seen with doses >200 mg/day 8:
- Bioavailability increases with lower daily doses
- Target plasma trough concentration (C24,trough) <0.3 mg/L to avoid severe toxicity
- Peak concentrations should remain <3-5 mg/L 8
Patients with low serum albumin are at increased risk for toxicity and may require closer monitoring or empiric dose reduction 7.
Clinical Pearls and Pitfalls
Common pitfalls to avoid:
- Do not use body surface area-based dosing >100 mg/m²/day—this increases toxicity without improving efficacy 3
- Do not continue treatment through severe cytopenias—hold and reduce dose 7
- Do not overlook renal function—failure to adjust for CrCl <50 mL/min significantly increases toxicity risk 7
Optimal patient selection:
- Best responses in patients with platinum-free interval >6 months 6
- Reasonable option for 4th-5th line therapy with similar benefit to earlier lines 9
- Consider in elderly patients or those with poor performance status where IV regimens are poorly tolerated 2
The fixed 50 mg daily × 14 days every 3 weeks regimen represents the evidence-based standard for oral etoposide in recurrent ovarian cancer, balancing modest activity against acceptable toxicity in this palliative setting 1, 2.